Assessment of COVID-19 Vaccine Effectiveness Against SARS-CoV-2 Infection, Hospitalization and Death in Mexican Patients with Metabolic Syndrome from Northeast Mexico: A Multicenter Study DOI Creative Commons
Beatriz Silva-Ramírez, Katia Peñuelas-Urquides, Brenda Leticia Escobedo-Guajardo

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(3), P. 244 - 244

Published: Feb. 27, 2025

Background/Objectives: Metabolic syndrome (MetS) is a predisposing factor for severe COVID-19. The effectiveness of COVID-19 vaccines in patients with MetS has been poorly investigated. aim this study was to evaluate the vaccination before (BO) and after Omicron (AO) SARS-CoV-2 variant MetS. Methods: This retrospective observational carried out total 3194 PCR or rapid antigen test. main outcomes were vaccine against infection, hospitalization death resulting from Results: BO, only two doses BNT162b2 effective lost AO. Also, doses, BNT162b2, ChAdOx1 CoronaVac BO; however, AO, effective. Regarding as an outcome COVID-19, whereas 100% BO presentation sore throat increased regardless type, dyspnea diminished CoronaVac. Conclusions: impacted vaccines’ A tailored scheme should be implemented due varying rates observed our study.

Language: Английский

Assessment of COVID-19 Vaccine Effectiveness Against SARS-CoV-2 Infection, Hospitalization and Death in Mexican Patients with Metabolic Syndrome from Northeast Mexico: A Multicenter Study DOI Creative Commons
Beatriz Silva-Ramírez, Katia Peñuelas-Urquides, Brenda Leticia Escobedo-Guajardo

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(3), P. 244 - 244

Published: Feb. 27, 2025

Background/Objectives: Metabolic syndrome (MetS) is a predisposing factor for severe COVID-19. The effectiveness of COVID-19 vaccines in patients with MetS has been poorly investigated. aim this study was to evaluate the vaccination before (BO) and after Omicron (AO) SARS-CoV-2 variant MetS. Methods: This retrospective observational carried out total 3194 PCR or rapid antigen test. main outcomes were vaccine against infection, hospitalization death resulting from Results: BO, only two doses BNT162b2 effective lost AO. Also, doses, BNT162b2, ChAdOx1 CoronaVac BO; however, AO, effective. Regarding as an outcome COVID-19, whereas 100% BO presentation sore throat increased regardless type, dyspnea diminished CoronaVac. Conclusions: impacted vaccines’ A tailored scheme should be implemented due varying rates observed our study.

Language: Английский

Citations

0